πŸ‡ΊπŸ‡Έ FDA
Patent

US 11851498

Anti-CD276 antibodies (B7H3)

granted A61KA61K2039/505A61K2300/00

Quick answer

US patent 11851498 (Anti-CD276 antibodies (B7H3)) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2300/00, A61K39/39558, A61K47/68031